FF
CSTL icon

FourThought Financial’s Castle Biosciences CSTL Stock Holding History

FourThought Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2K Hold
86
– – ﹤0.01% 1312
2022
Q2 		$2K Buy
86
+58
+207% +$1.35K ﹤0.01% 1317
2022
Q1 		$1K Hold
28
– – ﹤0.01% 1388
2021
Q4 		$1K Hold
28
– – ﹤0.01% 1423
2021
Q3 		$1K Hold
28
– – ﹤0.01% 1430
2021
Q2 		$2K Buy
+28
New +$1.85K ﹤0.01% 1353

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FourThought Financial's CSTL Position: Q3 2022 in Review

FourThought Financial held its Castle Biosciences (CSTL) position steady in Q3 2022 at 86 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

FourThought Financial first reported a position in CSTL in Q2 2021 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold CSTL as of Q3 2022.

  • FourThought Financial held 86 shares of Castle Biosciences worth $2K as of Q3 2022.
  • FourThought Financial left its Castle Biosciences share count unchanged in Q3 2022.
  • Castle Biosciences made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1312 holding.
  • FourThought Financial first reported a position in Castle Biosciences in Q2 2021 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.